ApalyRx and Vida Health Partner to Expand Cost-Effective, Integrated Weight-Loss Care for Employers
ApalyRx, a pharmacy technology platform designed to assess prescriptions in real time and route them to the lowest-cost fulfillment channel available under a health plan benefit, has announced a new partnership with Vida Health, a digital health company providing integrated, longitudinal cardiometabolic and behavioral health care.
The collaboration is designed to help self-funded employers provide health plan members with comprehensive clinical weight-loss care while improving access to prescribed medications at the lowest available cost to the plan. By combining Vida Health’s clinical care model with ApalyRx’s prescription pricing and fulfillment technology, the companies aim to connect medical care and medication access within the existing health benefit.
The partnership brings together two complementary components of the healthcare journey. Vida Health provides the clinical services, including care from board-certified obesity medicine physicians, registered dietitians, licensed therapists and health coaches. ApalyRx focuses on the pharmacy side, evaluating prescriptions in real time across multiple independent licensed suppliers and routing each prescription to the supplier offering the lowest available cost for the participating plan.
The companies say the model is intended to make medication access more closely aligned with clinical care while giving employers greater visibility into prescription spending.
Connecting Clinical Weight-Loss Care With Medication Access
Obesity and cardiometabolic conditions often require ongoing care that combines lifestyle interventions, behavioral health support and, when clinically appropriate, prescription medications. GLP-1 medications and other anti-obesity therapies have become an increasingly important component of treatment for eligible patients, but the cost of these medicines can create challenges for employers and health plans.
Through the new partnership, Vida Health will provide the clinical infrastructure for members receiving weight-management and cardiometabolic care. Its care teams include physicians specializing in obesity medicine, registered dietitians, licensed therapists and health coaches who provide whole-person support.
When clinically appropriate, Vida Health clinicians can prescribe anti-obesity medications, including GLP-1 therapies.
ApalyRx then addresses the medication fulfillment component. Rather than routing prescriptions through a single predetermined channel, its technology assesses each prescription and compares available pricing across multiple independent licensed suppliers. The prescription can then be routed to the channel offering the lowest cost under the plan.
The approach is intended to connect the clinical decision to a cost-conscious fulfillment process without requiring the member to navigate separate discount programs or cash-pay options.
Prescription Routing Operates Through the Health Plan Benefit
A central feature of the ApalyRx model is that prescriptions are processed through the health plan benefit rather than through cash-pay discount cards or coupons.
According to the companies, each prescription is billed to the employer’s third-party administrator (TPA) or carrier and adjudicated as a claim. This means member cost sharing can be reported through the plan administrator toward applicable deductibles and out-of-pocket maximums.
The companies also state that the approach is designed to maintain compliance with applicable Internal Revenue Service rules governing high-deductible health plans (HDHPs) and health savings accounts (HSAs).
This benefit-based structure is intended to provide employers with a clearer connection between pharmacy spending and the health plan itself. Instead of directing members to a separate discount mechanism, the prescription remains within the employer-sponsored benefit structure.
Another component of the model is prescription-level documentation. ApalyRx records each routing decision, creating documentation showing the amount paid by the plan, the alternative costs considered and the reason the prescription was routed to a particular fulfillment channel.
For employers operating under fiduciary responsibilities, including obligations associated with the Employee Retirement Income Security Act (ERISA) and the Consolidated Appropriations Act (CAA), the companies say this prescription-level information can provide an auditable record of pharmacy purchasing decisions.
Working Alongside Existing PBM and TPA Infrastructure
ApalyRx’s technology is designed to work alongside an employer’s existing pharmacy benefit manager (PBM) and TPA rather than replacing those organizations.
This distinction allows employers to add prescription-level price assessment and routing capabilities to their existing health benefit infrastructure.
Under the partnership, Vida Health remains focused on delivering clinical care and managing members through its digital health platform, while ApalyRx handles the prescription fulfillment and cost-assessment component.
The two companies therefore address different elements of the same member experience.
Vida’s clinicians determine appropriate treatment based on a member’s clinical circumstances. When medication is prescribed, ApalyRx evaluates the available fulfillment options and identifies the lowest-cost channel for that prescription under the applicable benefit.
This model is particularly relevant to weight-management programs, where ongoing medication use can represent a substantial component of overall treatment costs.
GLP-1 Medications Are Part of a Broader Pharmacy Model
Although the partnership places significant emphasis on weight-loss care and GLP-1 therapies, ApalyRx’s technology is not limited to anti-obesity medications.
The company states that its platform sources more than 8,000 National Drug Codes (NDCs) across multiple independent suppliers, with some medications sourced directly from manufacturers.
The same real-time prescription assessment is applied across prescriptions filled by enrolled members. This means the platform is designed to evaluate pharmacy costs beyond the specific class of medications used for obesity and cardiometabolic care.
For employers, this broader approach could provide a mechanism for applying prescription-level cost comparisons across different therapeutic categories rather than creating a standalone strategy exclusively for GLP-1 medications.
The companies’ partnership therefore combines a specific clinical focus on cardiometabolic and behavioral health with a broader pharmacy technology platform.
ApalyRx Reports More Than 321,000 Covered Lives Served
ApalyRx said it has served more than 321,000 covered lives since 2018 through its prescription offering.
The company also reports that its Rx offering has reduced spending by an average of 20% or more. These figures are company-reported and reflect ApalyRx’s experience with its offering rather than an independent evaluation of the new partnership with Vida Health.
The company views its prescription routing model as a way to help employers address the financial pressures associated with prescription drug coverage while maintaining access to medications prescribed by clinicians.
“Employers want to give employees and their families real access to the medications their clinicians prescribe, and they want to meet their fiduciary duty while doing it,” said Jerry Beinhauer, MD, founder and CEO of ApalyRx.
Beinhauer said Vida Health provides the clinical care intended to help members achieve treatment goals, while ApalyRx focuses on ensuring that prescriptions are filled at the lowest available cost to the plan.
He also emphasized the importance of keeping prescriptions on benefit so that eligible member cost sharing can count toward applicable plan requirements and so that plan fiduciaries have documentation supporting pharmacy purchasing decisions.
Vida Health Emphasizes Whole-Person Cardiometabolic Care
Vida Health brings its digital health and clinical care capabilities to the partnership.
The company’s model combines medical and behavioral health services, reflecting the multifaceted nature of cardiometabolic conditions. Members can receive support from physicians, dietitians, therapists and health coaches as part of an integrated care program.
Jason Macaleer, Chief Strategy Officer at Vida Health, said the effectiveness of cardiometabolic care depends in part on aligning clinical treatment with medication access.
“Cardiometabolic care works when the clinical program and medication access are aligned around the member,” Macaleer said.
He added that Vida’s care teams provide evidence-based, whole-person treatment and said the partnership with ApalyRx can give employers another approach to continuing coverage of medications rather than eliminating coverage or transferring the full medication cost to members.
Addressing Employer Challenges Around Weight-Loss Benefits
The partnership comes as employers and health plans continue to navigate the clinical and financial considerations associated with weight-management medications.
For employers, providing access to anti-obesity medications can involve balancing member demand, clinical appropriateness, benefit design and pharmacy spending. The cost of certain therapies can also make medication access a significant consideration when employers evaluate whether and how to include weight-loss treatments in their benefits.
The ApalyRx and Vida Health model is intended to address two parts of that equation simultaneously.
Vida Health provides the clinical framework through which members can receive evidence-based cardiometabolic and behavioral health support and, when appropriate, prescriptions for anti-obesity medications. ApalyRx then evaluates the prescription against available fulfillment channels to identify the lowest-cost option under the employer’s benefit.
By keeping the prescription within the health plan benefit, the companies say the model can provide employers with greater visibility into spending while preserving the connection between member cost sharing and plan administration.
Combining Digital Health and Pharmacy Technology
The partnership represents a broader convergence between digital healthcare delivery and pharmacy technology.
Digital health platforms can provide ongoing clinical engagement, monitoring and behavioral support, while pharmacy technology can address the cost and fulfillment side of treatment. Combining the two can create a more integrated pathway from clinical evaluation to prescription fulfillment.
For Vida Health, the collaboration adds a pharmacy technology component to its cardiometabolic care offering. For ApalyRx, it creates a connection between its prescription routing platform and a digital clinical care program focused on obesity, cardiometabolic health and behavioral health.
The companies intend to make these capabilities available to self-funded employers seeking to provide members with comprehensive weight-loss care and medication access through their existing health benefits.
As employers continue evaluating approaches to managing the clinical and financial aspects of weight-management programs, the ApalyRx-Vida Health partnership will focus on connecting care delivery, prescription fulfillment and benefit-based pharmacy pricing within a single member experience.
About ApalyRx
Founded in 2018, ApalyRx is the assessment and routing layer that sits in front of a self-funded employer’s pharmacy benefit. It prices every prescription across every available fulfillment channel in real time, including manufacturer direct and the plan’s own PBM, routes each script to the lowest available cost, and delivers it on benefit with a plan claim for every fill and a decision-level record for fiduciary oversight. ApalyRx holds no dispensing operation and no economic interest in where a prescription is filled. It works alongside existing PBMs and TPAs and charges only when it produces savings. Learn more at www.apalyrx.com.
About Vida Health
Vida Health is a value-based, virtual cardiometabolic care provider that matches members to the right level of care based on their metabolic instability. Its medication guidance system prioritizes lower-cost, high-value therapeutic alternatives across obesity, diabetes, hypertension, hyperlipidemia, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea (OSA), and chronic obstructive pulmonary disease (COPD). Vida serves members at all acuity levels, combining evidence-based prescribing with behavior change support and provider-led care.
The company’s multidisciplinary team of obesity medicine-certified physicians, nurses, registered dietitians, expert coaches, and licensed therapists delivers a whole-person approach that improves outcomes while reducing avoidable healthcare costs. Vida serves members in all 50 states and Washington, D.C., offers services in both English and Spanish, and operates on a value-based pricing model that centers on measurable health outcomes.